Biotherapeutics company MYOS RENS Technology (NASDAQ:MYOS) revealed on Wednesday that it has appointed Joseph Mannello as its interim chief executive officer with effect from 1 September 2016.

In addition, the company has named Victor Mandel to its board, filling a vacancy resulting from the recent resignation of Guiying Zhao.

Recently, Mannello has served as a member of the company's board since December 2015 and as an independent management consultant since May 2015.

Mannello previously worked as executive managing director and a member of the operating committee of Brean Capital LLC; executive managing director and head of corporate credit of Gleacher & Company; managing director and head of the corporate fixed income division of BNY Capital Markets; As well as founder and chief executive officer of Mendham Capital Group.

Most recently, Mandel has served as a director of MYOS RENS from December 2015 until March 2016.

Earlier in his career, Mandel was the founding of Criterion Capital Management; co-chair, director, chair of the Governance and Nominating Committee and member of the Audit and Strategy and Risk Policy Committees at Ambac Financial Group; a member of the board and audit committees of Comsys IT Partners, Broadpoint Gleacher Securities Group and XLHealth Corp; CFO of Circle.com; EVP Finance and Development of Snyder Communications; As well as VP at Goldman Sachs & Co.